Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
Top Cited Papers
- 13 December 2018
- journal article
- research article
- Published by Elsevier BV in European Urology Oncology
- Vol. 2 (6), 670-676
- https://doi.org/10.1016/j.euo.2018.11.007
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology, 2016
- German Multicenter Study Investigating177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer PatientsJournal of Nuclear Medicine, 2016
- PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013Journal of Nuclear Medicine, 2016
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyEuropean Urology, 2016
- Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)European Urology, 2015
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2015
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancerJournal of Cellular Biochemistry, 2003